Send to

Choose Destination
Recenti Prog Med. 2016 Apr;107(4):193-8. doi: 10.1701/2218.23932.

[Ramucirumab-paclitaxel as second-line therapy for advanced gastric cancer: Poliambulanza experience].

[Article in Italian]

Author information

UO di Oncologia, Fondazione Poliambulanza, Brescia, Italia.


We reported the cases of two patients affected by metastatic gastric cancer exposed to second line therapy with ramucirumab plus paclitaxel after progression. Both obtained a fast marker reduction with a very favourable toxicity profile. In the first case, a woman affected by peritoneal carcinomatosis, the disease had been stable for 8 months despite of the chemotherapy suspension after 3 cycles; whereas in the second case, a highly symptomatic man with a heavy tumor load (gastric tumor and multiple bone, node and peritoneal metastases) obtained an immediate clinical benefit even if of relatively short duration with a good tolerability.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Il Pensiero Scientifico Editore
Loading ...
Support Center